Bill Taranto

So I think we need some regulatory oversight on some of the areas.

But it will have a massive impact on the broader industry, as I said, around things like supply chain, clinical execution, regulatory quality.

All the things that, at least for pharma, make a pharma run.

And that's, of course, for us as a pharma investor, where we're focused going forward.

You know, that's certainly the hope.

You know, if you think about the AI and ML and drug discovery, you know, the whole idea is if you can speed up, you know, get it

an asset five years sooner than you did, that's the value.

And so if you think about AI and clinical trial, this whole zero gravity clinical trial or, or technology and clinical trial, if you can do things like recruiting, the biggest issue for the pharma companies is recruiting, um, for drug discovery, right?

And recruitment and clinical trial is really difficult.

And now that the FDA has mandated that we have to have diversity in clinical trial recruiting, you can't be a, you know, a white male over 50, um,

AI is going to help us do that.

We actually invested in a company called NPower recently that does clinical trial diversity recruiting.

And the whole background is an AI backbone that looks at the community level and tries to help identify patients.

So one of the things we're going to see is it's going to speed up clinical trial recruiting, which will speed up clinical trials.

AI is going to also help with site management tremendously, making sure that patients stay within the clinical trial.

I think it's going to have a pretty large impact going forward if you think about where it can be used in, you know, maybe not all facets of clinical trial, but certainly in certain areas, like I said, around recruitment, I think site management, patient management.

I think those three areas are really right for AI to have an impact.

But I said to probably that, you know, the biggest problem for us is trying to get enough patients into a trial.

And every pharma company is doing hundreds and hundreds of trials.

And I think AI is going to help us identify those patients on a more global basis as well.